Adage Capital Partners
KYTX icon

Adage Capital Partners’s Kyverna Therapeutics KYTX Stock Holding History

Adage Capital Partners’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.46M Hold
500,000
– – 0.01% 820
2026
Q1 		$4.32M Sell
500,000
-1,166,666
-70% -$9.72M 0.01% 784
2025
Q4 		$15.7M Buy
+1,666,666
New +$12.4M 0.02% 562
2024
Q3 		– Sell
-75,000
Closed -$563K – 948
2024
Q2 		$563K Sell
75,000
-500,000
-87% -$7.64M ﹤0.01% 814
2024
Q1 		$14.3M Buy
+575,000
New +$16M 0.03% 534

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Adage Capital Partners's KYTX Position: Q2 2026 in Review

Adage Capital Partners held its Kyverna Therapeutics (KYTX) position steady in Q2 2026 at 500,000 shares worth $4.46M. The position accounts for 0.01% of the portfolio, ranked #820.

Adage Capital Partners first reported a position in KYTX in Q1 2024 and has held it in 5 quarters since. The position peaked at $15.7M in Q4 2025. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Adage Capital Partners held 500,000 shares of Kyverna Therapeutics worth $4.46M as of Q2 2026.
  • Adage Capital Partners left its Kyverna Therapeutics share count unchanged in Q2 2026.
  • Kyverna Therapeutics made up 0.01% of Adage Capital Partners's portfolio in Q2 2026, its #820 holding.
  • Adage Capital Partners first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • Adage Capital Partners's Kyverna Therapeutics position peaked at $15.7M in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.